Shares of KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) have received a consensus rating of "Reduc

Founder of The LSM Group to support KALA's growth across its existing business and potential acquisi

Kala Bio, Inc. (NASDAQ:KALA) ("Kala") and Virotek Inc. ("Virotek") today announced t

Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tues

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday&#3

Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-register

ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Viro

Kala Bio (NASDAQ:KALA) reported quarterly losses of $(21.32) per share. This is a 75.11 percent incr

KALA BIO (NASDAQ: KALA - Get Free Report) is anticipated to release its Q2 2026 results before the m

Kala Bio (NASDAQ:KALA) reported quarterly losses of $(0.14) per share which beat the analyst consens

KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it

ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the

ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “C

Kala Bio (NASDAQ:KALA) reported quarterly earnings of $0.86 per share which beat the analyst consens

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen I

Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both s

Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opport

Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable

The company confirmed that BIRA is now live in client-controlled environments, marking its entry int

Kala Bio launches BIRA AI agent for biotech research, marking a shift to commercial deployment and a

KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given a consensus recommendation of "Hold"

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strat

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strat

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

US stocks mixed, Dow down 300 points. Dow down 0.71%, Nasdaq up 0.21%, S&P 500 down 0.13%. Energ

Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the a

US stocks traded mixed, with Dow down 0.63% while NASDAQ and S&P 500 rose. Energy shares rose by

Is KALA the Palantir of biotech? Kala Bio Inc. pivots to agentic AI with a new platform shipping in

Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping

Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within

Younet AI Partners with KALA BIO to Deploy AI Infrastructure for the Biotech Industry Vancouver, Bri

KALA BIO (KALA) shares rose after unveiling a strategic initiative to build an on-premises AI infras

KALA BIO (KALA) shares rose after unveiling a strategic initiative to build an on-premises AI infras

Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology in

ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “C

KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given an average recommendation of "Hold" b

Indaptus Therapeutics surged 64.65% in after-hours trading following a major insider investment and